Kevin Krause
Corporate Officer/Principal at AN2 THERAPEUTICS, INC.
Net worth: 63 509 $ as of 2024-05-30
Profile
Kevin Krause is currently the Chief Strategy Officer at AN2 Therapeutics, Inc. He previously worked as the Senior Director-Corporate Development at Achaogen, Inc. from 2015 to 2019 and as a Member-Clinical Microbiology at Cerexa, Inc. from 2010 to 2014.
He received an undergraduate degree from San Francisco State University and an MBA from Haas School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AN2 THERAPEUTICS, INC.
0.11% | 2024-03-14 | 31,914 ( 0.11% ) | 63 509 $ | 2024-05-30 |
Kevin Krause active positions
| Companies | Position | Start |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Corporate Officer/Principal | 2021-07-31 |
Former positions of Kevin Krause
| Companies | Position | End |
|---|---|---|
| ACHAOGEN | Corporate Officer/Principal | 2019-05-31 |
Cerexa, Inc.
 Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Corporate Officer/Principal | 2014-11-30 |
Training of Kevin Krause
| Haas School of Business | Masters Business Admin |
| San Francisco State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AN2 THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Health Technology |
- Stock Market
- Insiders
- Kevin Krause
